Risk of differentiation syndrome with enasidenib, warns US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1732卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55460-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[1] US FDA warns of increased myopathy risk with Zocor
[J]. Reactions Weekly, 2010, 1294 (1) : 1 - 1
[2] Risk of differentiation syndrome with decitabine, warns the NPRA in Malaysia
[J]. Reactions Weekly, 2022, 1887 (1) : 3 - 3
[3] Oral sodium phosphates: acute renal failure risk, warns US FDA
[J]. Reactions Weekly, 2006, 1101 (1) : 2 - 2
[4] Rituxan associated with PML, warns US FDA
[J]. Reactions Weekly, 2007, 1133 (1) : 3 - 3
[5] US FDA warns of hypericum/indinavir interaction
[J]. Reactions Weekly, 2000, 789 (1) : 2 - 2
[6] FDA warns of seizure risk with dalfampridine
[J]. Reactions Weekly, 2012, 1412 (1) : 2 - 2
[7] Enasidenib-induced Sweet syndrome with differentiation syndrome
Mohamed, Amr
[J]. CLINICAL CASE REPORTS, 2021, 9 (05):
[8] US FDA warns about ibuprofen and aspirin interaction
[J]. Reactions Weekly, 2006, 1119 (1) : 2 - 2
[9] US FDA warns Pfizer over tardy pharmacovigilance
[J]. Reactions Weekly, 2010, 1306 (1) : 2 - 2
[10] US FDA warns against fenfluramine/phentermine combination
[J]. Reactions Weekly, 1997, 662 (1) : 2 - 2

← 1 2 3 4 5 →